Evonik achieved a 24 percent increase in second-quarter adjusted EBITDA to €630 million, bolstered by higher sales volumes and prices in its Animal Nutrition business. Regional shipping bottlenecks outside Europe temporarily constrained Asian competitors, creating an economic windfall that prompted the specialty chemicals producer to raise its full-year guidance.

Global specialty chemicals leader Evonik reported strong second-quarter results for 2026, with overall revenue rising 11 percent and net income reaching €84 million. Performance was largely driven by the Advanced Technologies segment, where sales increased 9 percent to €1,647 million. Within this division, the Animal Nutrition business posted significant growth, supported by higher volumes and improved selling prices for essential amino acids. Disruption to maritime routes, particularly around the Arabian Peninsula and the Strait of Hormuz, hampered raw material purchases for Asian competitors, resulting in market supply shortages that worked to Evonik’s operational advantage. "We are witnessing a warm summer rain," stated Chief Executive Officer Christian Kullmann. "But unfortunately, this does not change the fundamental challenges for our industry."

Chief Executive Officer Christian Kullmann

To ensure long-term competitiveness amid broader market headwinds, the company is advancing its "Evonik Tailor Made" restructuring program. Alongside structural savings, free cash flow rebounded to €49 million for the quarter. Following the strong quarterly performance, Evonik raised its full-year 2026 adjusted EBITDA outlook to between €2.0 billion and €2.2 billion.